NBCC’s advocacy has resulted in more than $3.9 billion federal dollars for breast cancer research.
Breast cancer accounts for nearly a quarter of all cancers in women worldwide.
The DOD BCRP was created as a result of NBCC’s “$300 Million More” campaign to increase federal funding for breast cancer research.
NBCC applauds today’s Supreme Court decision in California v. Texas which preserves the ACA and saves health care coverage for millions of Americans.
Making the Most of August Recess, Upcoming Townhall Meetings, and other Public Policy Updates.
The National Breast Cancer Coalition is proud to announce bipartisan support for a bill to waive onerous health care waiting periods for those with metastatic breast cancer.
We all want new treatments to “work” for breast cancer patients. For the National Breast Cancer Coalition (NBCC), that means the investigational therapy will significantly prolong overall survival (OS) without adverse impact on quality of life. We expect that the evidence of that benefit will be shown by well-designed, well-conducted prospective randomized clinical trials, sufficiently designed to support that result. Unfortunately, that has not been the case with TECENTRIQ® (atezolizumab) in first-line treatment of advanced or metastatic triple-negative breast cancer (TNBC).